PMC:7283670 / 62250-63162 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T363","span":{"begin":67,"end":69},"obj":"Disease"},{"id":"T364","span":{"begin":126,"end":134},"obj":"Disease"},{"id":"T365","span":{"begin":198,"end":206},"obj":"Disease"}],"attributes":[{"id":"A363","pred":"mondo_id","subj":"T363","obj":"http://purl.obolibrary.org/obo/MONDO_0005773"},{"id":"A364","pred":"mondo_id","subj":"T364","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A365","pred":"mondo_id","subj":"T365","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T579","span":{"begin":43,"end":51},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T580","span":{"begin":218,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T581","span":{"begin":417,"end":421},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T582","span":{"begin":592,"end":596},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T155","span":{"begin":33,"end":42},"obj":"Chemical"},{"id":"T156","span":{"begin":55,"end":65},"obj":"Chemical"},{"id":"T157","span":{"begin":67,"end":69},"obj":"Chemical"},{"id":"T158","span":{"begin":143,"end":153},"obj":"Chemical"},{"id":"T159","span":{"begin":443,"end":453},"obj":"Chemical"},{"id":"T160","span":{"begin":694,"end":700},"obj":"Chemical"},{"id":"T161","span":{"begin":821,"end":825},"obj":"Chemical"}],"attributes":[{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_73516"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A161","pred":"chebi_id","subj":"T161","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T637","span":{"begin":0,"end":428},"obj":"Sentence"},{"id":"T638","span":{"begin":429,"end":726},"obj":"Sentence"},{"id":"T639","span":{"begin":727,"end":912},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T221","span":{"begin":684,"end":689},"obj":"Phenotype"}],"attributes":[{"id":"A221","pred":"hp_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1888","span":{"begin":80,"end":92},"obj":"Species"},{"id":"1889","span":{"begin":288,"end":300},"obj":"Species"},{"id":"1890","span":{"begin":463,"end":475},"obj":"Species"},{"id":"1891","span":{"begin":649,"end":661},"obj":"Species"},{"id":"1892","span":{"begin":752,"end":764},"obj":"Species"},{"id":"2061","span":{"begin":55,"end":65},"obj":"Chemical"},{"id":"2062","span":{"begin":143,"end":153},"obj":"Chemical"},{"id":"2063","span":{"begin":443,"end":453},"obj":"Chemical"},{"id":"2125","span":{"begin":105,"end":124},"obj":"Disease"},{"id":"2126","span":{"begin":126,"end":134},"obj":"Disease"},{"id":"2127","span":{"begin":198,"end":206},"obj":"Disease"},{"id":"2128","span":{"begin":684,"end":689},"obj":"Disease"}],"attributes":[{"id":"A1888","pred":"tao:has_database_id","subj":"1888","obj":"Tax:9606"},{"id":"A1889","pred":"tao:has_database_id","subj":"1889","obj":"Tax:9606"},{"id":"A1890","pred":"tao:has_database_id","subj":"1890","obj":"Tax:9606"},{"id":"A1891","pred":"tao:has_database_id","subj":"1891","obj":"Tax:9606"},{"id":"A1892","pred":"tao:has_database_id","subj":"1892","obj":"Tax:9606"},{"id":"A2061","pred":"tao:has_database_id","subj":"2061","obj":"MESH:C000606551"},{"id":"A2062","pred":"tao:has_database_id","subj":"2062","obj":"MESH:C000606551"},{"id":"A2063","pred":"tao:has_database_id","subj":"2063","obj":"MESH:C000606551"},{"id":"A2125","pred":"tao:has_database_id","subj":"2125","obj":"MESH:D018352"},{"id":"A2126","pred":"tao:has_database_id","subj":"2126","obj":"MESH:C000657245"},{"id":"A2127","pred":"tao:has_database_id","subj":"2127","obj":"MESH:C000657245"},{"id":"A2128","pred":"tao:has_database_id","subj":"2128","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14\nSecondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020"}